
achiev
biotech post solid gain come rough nbi vs
look five classic driver think sector pois strong
start anoth year out-performance despit under-perform
larg confin select larg cap turn exacerb neg fund
flow trend think balanc macro factor remain posit shortag
upcom catalyst accommod regulatori environ strong commerci
perform albeit somewhat mix capit market environ fairli reason
valuat larg bullish space would particularli focus
smaller cap side bold
year held littl charm full year biotech
slightli outperform broader market nbi vs sector
limp ye under-perform nbi vs larg cap
hit disproportion think driven larg misstep celg
neg fund flow dynam quarter rest biotech fundament
fairli good shape posit sector outlook year point
signific catalyst tap note mani industry-driv catalyst
tap includ abbv rova-t sclc registr data
phase pnh data praluent odyssey outcom data
thank much dr gottlieb fda track record increas
product effici goe back mani year think new
commission agenda gener seem focus improv
health outcom foster competit favor innov
capit market environ take littl
rel scarc favor macro factor tax reform
think head someth think support two
deal announc final day decemb could benefit fund flow
dynam note decidedli neg
commerci perform think closely-watch launch biib
spinraza dupix continu impress see
survey work expect establish agent like tecfidera
achiev potenti aid recent healthi price increas
valuat exactli stretch trade ep
biotech current trade rel line averag
note sector premium bounc
histor low jan/feb remain well average
name would highlight among larger cap would focu
vehicl meaning out-performance term small cap particularli
like bold
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
tabl content
invest conclus like set-up biotech
name like bold
lot catalyst tap well year whither
regulatori set strong time especi like hear dr
fda fundament strong time rhetor match number
valuat look pretti reason us
histor nbi ntm price-to-earnings nbi premium
page
invest conclus like set-up biotech
biotech sector put decent perform nbi compar
 despit rough look driver sector commerci
perform catalyst flow regulatory/polici environ capit market environ
valuat balanc like set-up would select buyer detail
page
name like bold
pivot data due clariti expect eu ip front
launch soliri mgwhich think may steeper launch curv
indic given natur diseas patient wareh dynamicsw
think set good year execut new manag team
ocrevu launch impact ms market focu
survey feedback indic increas ms market stabil think
expect biib ms franchis look achiev commun could
improv think spinraza launch continu impress enter second
year market addit commerci perform think recent move taken
strengthen tecfidera franchis valu aducanumab suppos
complet enrol on-going phase trial start work stock
expect fda pegvalias approv late may see
signific catalyst stock year newli profit compani also
anticip share demand ep visibl come focu multipl clinic
catalyst expect name outperform
bold first look clinic data bold on-going xlmtm trial expect
near-term follow fairli regular data cadenc addit program
throughout year see multipl valu creat catalyst year bold
recent assumpt coverag
like chanc favor fda decis fostamatinib itp
pdufa date april see key catalyst stock year
recent assumpt coverag
think read-through phase data fgen hif compound
posit key de-risk event akebia vadadustat year
recent initi coverag
page
lot catalyst tap well year whither
almost alway space chock-ful clinic regulatori catalyst view
next month differ inde among larg cap smaller-cap name
coverag see numer tone-set clinic event like keep attent
biotech investor includ one list
top-lin data phase triniti trial rova-t sclc follow
potenti file later commerci launch mavyret hcv on-going
potenti regulatori approv launch venclexta r/r cll potenti
elagolix endometriosi approval/launch addit phase readout
upadacitinib file ra
soliri myasthenia gravi launch phase pnh data
follow regulatori file commerci launch soliri phase nmo data
spinraza ww commerci launch on-going potenti read-out phase
trial tysabri acut stroke potenti data
trial evalu vs tecfidera follow nda submiss
enrol complet phase aducanumab engag emerg trial
potenti phase raxatrigin data sciatica
celg potenti ozanimod ms approv late enrol complet phase
north trial evalu ozanimod uc phase readout luspatercept
beta-thalassemia md revlimid phase augment data follicular
 potenti dupix asthma approval/launch potenti fasinumab phase
osteoarthr pain data expect praluent odyssey outcom data
file cscc
smaller-cap name also big upcom catalyst first half year
set particularli busi smaller cap name coverag
describ previous near-term like earli month bold disclos
preliminari data cohort phase aspiro trial xlmtm first clinic
data weve seen gene therapi program see launch note april
import day pdufa date fostamatinib itp
expect posit decis fda see launch note
said catalyst tend import space term sympathi move
overal sentiment varieti front bit anomali light
deal-flow particularli compar prior year larger-scal deal jnj acquisit
actelion gild kite acquisit drive averag deal size higher
inde look flow sinc note number size deal actual
tend rel consist year see least eight major deal averag
deal valu rang tax reform pass two deal announc
final week decemb think sector pois see
return least averag level weve seen prior year
page
page
 deal size number dealsnumb dealsavg deal size
regulatori set-up strong time
especi like hear dr gottlieb
clear despit polit theater come all-too-conveni critiqu fda
mani shortcom fact agenc long well establish histori
increas effici product inde sinc trend absolut approv
number percentag first cycl applic approv steadili climb
number nme approv surpass even strong number neither trend
straight line trend decidedli right direct see chart
strong
time
rhetor match
new fda commission scott gottlieb gener industry-friendli approach like
hear fda certainli close key artifici barrier gener competit
like deleteri impact innov margin fda prioriti around improv
public health innov increas competit eye toward even effici
nimbl review sure posit sector moreov one never
complet sure presid trump issu dead alway remain risk
member congress rais issu well state effort think price
debat larg die would also highlight spiral healthcar cost
inde matter nation import put drug cost proper context compar
servic deliveri care drug still account less total spend
percentag still lower decad ago project
remain
page
page
 spendest spend healthcar delivery/servic spend projectedprescript drug spend projectedhealthcar delivery/servic spendprescript drug spendprescript drug spendprescript drug spend projectedforecast
fund flow dedic biotech healthcar mutual fund decidedli neg sinc
octob outflow past week recent neg streak brought net
flow outflow follow two year outflow number
often tend follow indic think time recoveri strong move overal
asset price either direct trend weekli number becom import driver
trend biotech see out-performance think need see period sustain inflow
havent seen recent week though could chang
also track breadth ratio compar number firm report inflow vs
number report outflow exampl equal number firm report inflow outflow
one week breadth ratio would valu indic fund outflow
inflow given week ratio current stand close
page
environ improv note ipo follow-on activ increas
didnt see biotech go public late-octob late-januari ipo
activ remain fairli sluggish four ipo pick remaind
year bring ipo count exceed total also end
follow-on activ financ compar
think fairli good sign far capit market environ goe
page
valuat look pretti reason us
lastli highlight herein take valuat sure valuat rock bottom
howev view appear exactli stretch either ep
ntm ep large-cap biotech current trade fairli line
averag note sector premium bounc
histor low january/februari remain well
averag
page
histor nbi ntm price-to-earnings nbi premium
think select mid-cap may also provid good set-up inde note last
year biotech compani market cap rang averag ltm revenu multipl
larg rang time excurs outsid rang today
name howev compar valuat take-out multipl
strateg buyer will pay may seem intuit valuat gone higher
recent year inde look actual number would seem confirm impress
take-out multipl increas steadili last year
page
